Polycystic Ovarian Syndrome - Pipeline Review, H2 2017

Publisher Name :
Date: 29-Aug-2017
No. of pages: 54
Inquire Before Buying

Polycystic Ovarian Syndrome - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Polycystic Ovarian Syndrome - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome - Overview
Polycystic Ovarian Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Ovarian Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bayer AG
Crinetics Pharmaceuticals Inc
EffRx Pharmaceuticals SA
Millendo Therapeutics Inc
Novartis AG
Ogeda SA
Vicore Pharma AB
Polycystic Ovarian Syndrome - Drug Profiles
BAY-1161116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fezolinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDSCR-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LIK-066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metformin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MLE-4901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Ovarian Syndrome - Dormant Projects
Polycystic Ovarian Syndrome - Discontinued Products
Polycystic Ovarian Syndrome - Product Development Milestones
Featured News & Press Releases
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for MLE4901 at ENDO 2017 and Kisspeptin 2017
Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364
Nov 03, 2016: Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting
Nov 02, 2016: Millendo Therapeutics to present data on MLE-4901 program at Society for Endocrinology British Endocrine Societies Conference
Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Bayer AG, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals SA, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics Inc, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Novartis AG, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Ogeda SA, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2017
Polycystic Ovarian Syndrome - Dormant Projects, H2 2017
Polycystic Ovarian Syndrome - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Contraceptives Market Research Report 2017
    Published: 19-Oct-2017        Price: US 2900 Onwards        Pages: 113
    In this report, the global Contraceptives market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Contraceptives in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global Topical Contraceptive Market Research Report 2017
    Published: 17-Oct-2017        Price: US 2900 Onwards        Pages: 121
    In this report, the global Topical Contraceptive market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Topical Contraceptive in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic ren......
  • Premenstrual Syndrome - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 28
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premenstrual Syndrome - Pipeline Review, H2 2017, provides an overview of the Premenstrual Syndrome (Women's Health) pipeline landscape.Premenstrual syndrome (PMS) is a collection of physical and emotional symptoms related to a woman's menstrual cycle. Premenstrual syndrome has a wide variety of symptoms, including mood swings, tender breasts, food cravings, fatigue, irritability and depression.Repo......
  • Women Infertility - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 187
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cram......
  • Global Bacterial Vaginosis Drug Market Professional Survey Report 2017
    Published: 09-Oct-2017        Price: US 3500 Onwards        Pages: 113
    This report studies Bacterial Vaginosis Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bayer - Pfizer - Sanofi - Piramal - Abbott - ......
  • Global Postmenopausal Vaginal Atrophy Treatment Market Research Report 2011-2023
    Published: 03-Oct-2017        Price: US 1940 Onwards        Pages: 85
    Summary Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase. The global Postmenopausal Vaginal Atrophy Treatment market will reach xxx Mill......
  • Global Menopause Partnering 2010-2017
    Published: 01-Oct-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Menopause Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understan......
  • Global Contraception Partnering 2010-2017
    Published: 01-Oct-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Contraception Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides under......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs